New study tests geriatric support for seniors with gut cancers
NCT ID NCT04674267
First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times
Summary
This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to cancer treatment can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online fitness questionnaire is easy to use and if geriatric consultations reduce unplanned hospital visits. The goal is to learn how to better support this age group during cancer care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 147 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who are age 65+ at time of initial consult at DF/BWCC * Diagnosed with a gastrointestinal cancer, including: cancers of the esophagus, stomach, pancreas, liver, bile duct, ampulla, colon, rectum, or anus, as well as neuroendocrine tumors. * Continuing care at DF/BWCC beyond initial consult visit Exclusion Criteria: * Patients less than age 65 at time of initial consultation appointment with DF/BWCC. * Patients who are not continuing care at DF/BWCC beyond first consult visit. * Not proficient in English, Spanish, Haitian Creole, Portuguese, Traditional Chinese, Arabic, or Russian * Patient who are not considered appropriate for enrollment due to complex medical, social, or other situation as determined by their primary oncology team. * Participants with psychiatric illness/social situations that would limit compliance with study requirements.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ampullary cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Immunotherapy added to standard treatment aims to save the anus in Ultra-Low rectal cancer
- Can a Three-Drug combo crack pancreatic Cancer's defenses?
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Can a blood test before pancreatic surgery predict a dangerous leak?